Managed Access Programs for ETB115, Eltrombopag

Meta-analysis - Eltrombopag

NCT01235988 ·Status: COMPLETED

Eltrombopag for the Treatment of Thrombocytopenia Due to Low- and Intermediate Risk Myelodysplastic Syndromes

NCT02912208 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2

Study of Eltrombopag in Platelet Refractory Thrombocytopenia

NCT01194167 ·Status: WITHDRAWN ·Phase: PHASE2

Avatrombopag for the Treatment of Thrombocytopenia in Adults Scheduled for a Surgical Procedure

NCT03326843 ·Status: TERMINATED ·Phase: PHASE3

Safety Study of Eltrombopag Combined With Azacitidine to Treat Myelodysplastic Syndrome (MDS)

NCT01481220 ·Status: COMPLETED ·Phase: PHASE1

Clinical Evaluation of Eltrombopag in Chronic Idiopathic Thrombocytopenic Purpura (ITP)

NCT00828750 ·Status: COMPLETED ·Phase: PHASE3

Safety and Efficacy of Eltrombopag at Escalated Doses

NCT01880047 ·Status: COMPLETED ·Phase: PHASE2

Efficacy and Safety of Eltrombopag In Patients With Severe and Very Severe Aplastic Anemia

NCT01703169 ·Status: COMPLETED ·Phase: PHASE2

Use of Rituximab Treatment in Addition to Standard Care for Newly Presenting Thrombotic Thrombocytopenic Purpura

NCT00251277 ·Status: WITHDRAWN ·Phase: PHASE1/PHASE2

A Study of Eltrombopag or Placebo in Combination With Azacitidine in Subjects With International Prognostic Scoring System (IPSS) Intermediate-1, Intermediate-2 or High-risk Myelodysplastic Syndromes (MDS)

NCT02158936 ·Status: TERMINATED ·Phase: PHASE3

Clinical Management of Argatroban in Patients With Heparin Induced Thrombocytopenia Type II

NCT00861692 ·Status: COMPLETED ·Phase: PHASE2

Efficacy of a Personalized Caplacizumab Regimen Based on ADAMTS13 Activity Monitoring in Adult aTTP

NCT04720261 ·Status: TERMINATED ·Phase: PHASE2

Eltrombopag in Second Line Adult Primary Immune Thrombosytopenia

NCT02402998 ·Status: COMPLETED ·Phase: PHASE2

Eltrombopag for Thrombocytopenia in Patients With Relapsed Multiple Myeloma

NCT01484314 ·Status: TERMINATED ·Phase: PHASE2

Study of rADAMTS-13 (SHP655) in the Treatment of Participants With Acquired Thrombotic Thrombocytopenic Purpura (aTTP)

NCT03922308 ·Status: COMPLETED ·Phase: PHASE2

Eltrombopag in Myelodysplastic Syndrome (MDS) Patients With Thrombocytopenia

NCT01286038 ·Status: TERMINATED ·Phase: PHASE1

A Study to Assess the Ability of Eltrombopag to Induce Sustained Response Off Treatment in Subjects With ITP

NCT03524612 ·Status: COMPLETED ·Phase: PHASE2

Study Of Eltrombopag in Healthy Subjects and Volunteers With Mild, Moderate or Severe Hepatic Impairment

NCT00359463 ·Status: COMPLETED ·Phase: PHASE1

Eltrombopag for Post Transplant Thrombocytopenia

NCT01000051 ·Status: COMPLETED ·Phase: PHASE2

Efficacy and Safety Study of Argatroban to Treat Heparin-Induced Thrombocytopenia

NCT00198588 ·Status: COMPLETED ·Phase: PHASE3

Evaluation of Argatroban Injection in Pediatric Patients Requiring Anticoagulant Alternatives to Heparin

NCT00039858 ·Status: COMPLETED ·Phase: PHASE4

Efficacy and Safety Study of Eltrombopag in Pediatric Patients With Thrombocytopenia From Chronic Idiopathic Thrombocytopenic Purpura (ITP)

NCT00908037 ·Status: COMPLETED ·Phase: PHASE2

Eltrombopag To Reduce The Need For Platelet Transfusion In Subjects With Chronic Liver Disease And Thrombocytopenia Undergoing Elective Invasive Procedures

NCT00678587 ·Status: TERMINATED ·Phase: PHASE3

Single Patient Expanded Access Treatment Plan For The Investigational Product Narsoplimab

NCT04247906 ·Status: APPROVED_FOR_MARKETING

Eltrombopag vs Standard Front Line Management for Newly Diagnosed Immune Thrombocytopenia (ITP) in Children

NCT03939637 ·Status: COMPLETED ·Phase: PHASE3